Drug Interaction Report
8 potential interactions and/or warnings found for the following 2 drugs:
- cobicistat / darunavir / emtricitabine / tenofovir alafenamide
- maribavir
Interactions between your drugs
tenofovir darunavir
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Using tenofovir together with darunavir may increase the plasma concentrations of both medicines. You may need a special test or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as kidney problems. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
tenofovir cobicistat
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Using cobicistat together with tenofovir can increase the effects of tenofovir, which can cause new or worse kidney problems. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
tenofovir maribavir
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, maribavir
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with maribavir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters, both of which have been shown to be inhibited in vitro by maribavir at clinically relevant concentrations. Inhibition of transporter-mediated efflux in the intestine and possibly other organs such as the liver and kidney can increase the systemic bioavailability and decrease the clearance of affected substrates. When a single 0.5 mg dose of digoxin, a sensitive P-gp substrate, was coadministered with maribavir 400 mg twice daily in 18 study subjects, mean digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 21%, respectively, compared to digoxin administered alone. There are no clinical data regarding the use of maribavir with BCRP substrates, but increases in plasma concentrations of sensitive substrates such as rosuvastatin are expected according to the prescribing information.
MANAGEMENT: Caution is advised when maribavir is prescribed with drugs that are P-gp and/or BCRP substrates, particularly sensitive substrates or those with a narrow therapeutic range. Clinical and laboratory monitoring as well as dosage adjustments may be appropriate for some drugs whenever maribavir is added to or withdrawn from therapy. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of P-gp/BCRP inhibitors and for any dosage adjustments that may be required.
emtricitabine cobicistat
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Cobicistat is a medication used to boost the effects of some medications that treat HIV infection. However, using cobicistat together with other HIV medications, such as emtricitabine, may alter the blood levels and effects of both medications. Using emtricitabine with cobicistat may reduce or increase blood levels of cobicistat. Reduced blood levels of cobicistat may make cobicistat less effective and may cause overall HIV treatment to be less effective. Cobicistat may increase blood levels of emtricitabine which may increase the risk of side effects. Talk to your doctor or pharmacist if you have any questions on how to use these medications properly. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
darunavir maribavir
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, maribavir
Information for this minor interaction is available on the professional version.
cobicistat maribavir
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide, maribavir
Information for this minor interaction is available on the professional version.
Drug and food/lifestyle interactions
darunavir food/lifestyle
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Food can enhance the levels of darunavir in your body. Take darunavir with food. The type of food does not matter. This will make it easier for your body to absorb the medication. Swallow the whole tablets with a drink such as water or milk. Do not chew the tablets. Darunavir must be always be taken together at the same time as another medication called ritonavir (Norvir).
tenofovir food/lifestyle
Applies to: cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Genvoya
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) is used to treat HIV ...
Symtuza
Symtuza is an HIV treatment combining cobicistat, darunavir, emtricitabine, and tenofovir ...
Sunlenca
Sunlenca (lenacapavir) is used for the treatment of HIV-1 infection in heavily ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Complera
Complera (emtricitabine, rilpivirine, and tenofovir) is used to treat HIV infection. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.